High-risk monoclonal gammopathy of undetermined significance – to treat or not to treat?
Authors:
V. Maisnar 1; Hájek R Za Českou Myelomovou Skupinu 2
Authors‘ workplace:
IV. interní hematologická klinika, FN a LF UK Hradec Králové, 2Ústav klinické hematologie, FN Ostrava a LF Ostravské univerzity
1
Published in:
Transfuze Hematol. dnes,19, 2013, No. 1, p. 22-26.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Monoclonal gammopathy of undetermined significance (MGUS) is defined as a clinically silent, symptom-free state that does not meet the diagnostic criteria of multiple myeloma (MM), Waldenström macroglobulinemia, AL-amyloidosis or any other malignant lymphoproliferative disease. Long-term follow-up has demonstrated that this may be a pre-cancerous state with transformation into a malignant monoclonal gammopathy in approximately 1% of cases annually. Probably all cases of MM arise as a transformation of MGUS. In this overview, the author attempts to answer the key question, namely whether it is currently possible in some way to prevent the transformation of MGUS into MM or to at least to slow this down. The answer in MGUS patients is currently unequivocally NO. In view of the significantly higher risk of transformation in patients with asymptomatic multiple myeloma than in patients with MGUS, further analysis by the CMG will focus on this group of patients with the goal of selecting the group at highest risk and to subject this group to early and if possible non toxic treatment.
Key words:
acute leukaemia, minimal residual disease, cytogenetics, molecular cytogenetics, chromosome microdissection, next-generation sequencing, personalized medicine
Sources
1. Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies. Clin Chem 2000; 46:1230-8.
2. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmocytoma. Hematol Oncol Clin N Am 1997; 11: 71-87.
3. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573-89.
4. Kristinsson SY, Björkholm M, Anderson TM, et al. Patterns of survival and cause of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009; 94: 1714-20.
5. Kyle RA, Lust JA. Monoclonal gammopathies of undetermined significance. Semin Hematol 1989; 26: 176-200.
6. Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011; 17: 1243-52.
7. Landgren O, Waxman AJ. Multiple myeloma precursor disease. JAMA 2010; 304: 2397-404.
8. Durie BGM, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379-98.
9. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Froup (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009; 147: 22-42.
10. Dispenzieri A, Kyle R, Mateos MV, et al. International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma. Leukemia 2009; 23: 215-24.
11. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573-89.
12. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-9.
13. Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-7.
14. Paiva B, Vidriales MB, Perez JJ, et al. Multiparametric flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009; 94: 1599-602.
15. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparametric flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-92.
16. Lopez-Corral L, Gutierrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 2011; 17: 1692-700.
17. Bird JM, Owen RG, D´Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011; 154: 32-75.
18. Kumar SK, Dingli D, Lacy MQ, et al. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Br J Haematol 2008; 141: 205-11.
19. Maisnar V, Radocha J, Žák P, et al. 15-years of single center experience with stem cell transplantation for multiple myeloma. Haematologica/Hematol J 2011; 96 (Suppl. 1): 89/P-201.
20. Mateos MV, San Miguel JS, Garcia-Sanz R, et al. Results of QuiRedex study. Blood 2010; 116: A-1935.
21. Bladé J, Dimopoulos M, Rosinol L, et al. Smoldering (asymptomatic) multiple myeloma: Current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010; 28: 690-7.
22. Pérez-Persona E, Mateo G, Garcia-Sanz R, et al. Risk of progression in smoldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010; 148: 110-4.
23. Kyle RA, Durie BGM, Rajkumar SV, et al. A monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-27.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2013 Issue 1
Most read in this issue
- High-risk monoclonal gammopathy of undetermined significance – to treat or not to treat?
- Cryopreservation of blood – history, methods and the current status
- Antimycotic therapy: from prophylaxis to treatment
- Clinical aspects of „true“ non-secretory multiple myeloma